Aminoglutethimide: a Toxic Object Lesson in the Endocrine Management of Cancer

Abstract

Get full access to this article

View all access options for this article.

References

Camacho AM , Brough AJ , Cash R. & Wilroy RS

Adrenal toxicity associated with the administration of an anticonvulsant drug. Journal of

Pediatrics 1966; 68: 852-3.

Cash R. , Brough AJ , Cohen Mnp & Satoh PS

Aminoglutethimide as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. Journal of

Clinical Endocrinology and Metabolism 1967; 27: 1239-48.

Powles TJ The role of aromatase inhibitors in breast cancer. Seminars in Oncology 1983; 10: 20-4.

Thompson EA & Siiteri PK Utilisation of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatisation of androstenedione. Journal Biological Chemistry 1974; 249:5364-72.

Longcope C. , Pratt JH , Schneider SH & Fineberg SE

Aromatisation of androgens by muscle and adipose tissue in vivo. Journal of

Clinical Endocrinology and Metabolism 1978 ; 46: 146-52.

Miller WR & Forrest PM Oestradiol synthesis from C19 steroids by human breast cancers. British Journal of Cancer 1976; 33: 116-8.

Santen RJ , Worgul TJ , Samojlik E. , et al. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer. Correlation of hormonal data with clinical responses. Cancer Research 1982; 42: (suppl): 3397-401.

Samojlik E. & Santen RJ

Adrenal suppression with aminoglutethimide. II Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. Journal of

Clinical Endocrinology and Metabolism 1977; 45: 480-7.

Stuart Harris R , Dowsett M. , Bozek T. , et al. Low dose aminoglutethimide in treatment of advanced breast cancer. Lancet 1984; ii: 604-6.

10.

Dowsett M. , Harris AL , Stuart Harris R. , et al. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. British Journal of Cancer 1985; 52: 525-9.

11.

Young JA , Newcomer LN & Keller AM Aminoglutethimide induced bone marrow injury. Cancer 1984; 54: 1731-3.

12.

Harris AL , Hughes G. , Barrett AJ , Abusrewil S. , Dowsett M. & Smith IE Agranulocytosis associated with aminoglutethimide: pharmacological and marrow studies. British Journal of Cancer 1986; 54: 119-22.

13.

Rowell NP , Gilmore Oja & Plowman PN Aminoglutethimide as second-line hormonal therapy in advanced breast cancer: response and toxicity. Human Toxicology 1987 ; 6: 227-232.

14.

Harris AL , Dowsett M. , Stuart Harris R. & Smith IE Role of aminoglutethimide in male breast cancer. British Journal of Cancer 1986; 54: 657-60.

15.

Coombs RC , Goss P. , Dowsett M. , Gazet JC & Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 1984; ii: 1237-8.

16.

Rostom AY , Folkes A. , Lord C. , Notley RG , Schweitzer Faw & White WF Aminoglutethimide therapy foi advanced carcinoma of the prostate. British Journal of Urology 1982; 54: 552-5.

17.

Drago JR , Santen LJ & Lipson A. Clinical effect of aminoglutethimide, medical adrenalectomy, in the treatment of 43 patients with advanced prostate cancer. Cancer 1984; 53: 1447-50.

18.

Ponder Baj , Shearer RJ & Pocock RD Response to aminoglutethimide and cortisone acetate in advanced prostate cancer . British Journal of Cancer 1984; 50: 757-63,

19.

Murray R. & Pitt P. Medical adrenalectomy with aminoglutethimide in the treatment of advanced prostate cancer resistant to conventional therapy. In P roceedings of Third European Conference on Clinical Oncology, Stockholm. Abstract 203: p. 57.

20.

Plowman PN , Perry LA & Chard T. Androgen suppression by hydrocortisone with aminoglutethimide in orchidectomised men without prostatic cancer. British Journal of Urology 1987; 59: 255-257.